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The role of b2-microglobulin in amyloid
disease
b2-microglobulin (b2m) is the non-covalently bound
light chain of the major histocompatibility complex
class I (MHC I), wherein the protein plays an essential
role in chaperoning assembly of the complex for anti-
gen presentation (Fig. 1A) [1–3]. Wild-type b2m con-
tains 99 amino acids and has a classical b-sandwich
fold comprising seven anti-parallel b-strands that is
stabilized by its single inter-strand disulﬁde bridge
between b-strands B and F (Fig. 1B) [4–6]. The high
resolution structures of monomeric native b2m from
humans and several of its variants have been solved by
solution NMR [7–10] and X-ray crystallography [4,11–
16]. b2m contains ﬁve peptidyl–prolyl bonds, one of
which (His31-Pro32) adopts the thermodynamically
unfavoured cis-isomer in the native state (Fig. 1B)
[4,7,9]. Another interesting feature of monomeric
native b2m is the conformational dynamics of the
D-strand and the loop that connects the D- and
E-strands (the DE-loop) (Fig. 1B). This region forms
contacts with the MHC I heavy chain [17], but shows
dynamics on a microsecond to millisecond time-
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Several protein misfolding diseases are associated with the conversion of
native proteins into ordered protein aggregates known as amyloid. Studies
of amyloid assemblies have indicated that non-native proteins are responsi-
ble for initiating aggregation in vitro and in vivo. Despite the importance of
these species for understanding amyloid disease, the structural and dynamic
features of amyloidogenic intermediates and the molecular details of how
they aggregate remain elusive. This review focuses on recent advances in
developing a molecular description of the folding and aggregation mecha-
nisms of the human amyloidogenic protein b2-microglobulin under physio-
logically relevant conditions. In particular, the structural and dynamic
properties of the non-native folding intermediate IT and its role in the initi-
ation of ﬁbrillation and the development of dialysis-related amyloidosis are
discussed.
Abbreviations
b2m, b2-microglobulin; DRA, dialysis-related amyloidosis; MHC I, major histocompatibility complex class I; TFE, 2,2,2-triﬂuoroethanol.
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in different crystal structures (Fig. 1C,D) [13]. This
rationalizes hydrogen–deuterium exchange studies on
monomeric native b2m showing that the DE-loop
region exhibits enhanced backbone dynamics com-
pared with the non-covalently MHC I bound state
[18]. Notably, a link between the dynamic properties
of monomeric native b2m, particularly in the D-strand
and the DE-loop region, and its potential to assemble
into amyloid ﬁbrils has been proposed [7,10,11,18–20].
Catabolism of b2m following its dissociation from
the MHC I heavy chain occurs predominantly in the
proximal tubules in the kidney [21,22]. As a conse-
quence, the concentration of b2m circulating in the
serum of patients suffering from renal dysfunction is
enhanced up to 60-fold compared with healthy individ-
uals. This causes the deposition of b2m as amyloid
ﬁbrils in osteoarticular tissues, leading to pathological
bone destruction and the condition known as dialysis-
related amyloidosis (DRA) (Fig. 2) [23]. However, a
poor correlation between the b2m concentration in the
serum and ﬁbril load in osteoarticular tissues in long-
term dialysis patients suggests that additional factors
must be responsible for the initiation of b2m aggrega-
tion in vivo [24]. Consistent with these results, in vitro
studies have shown that b2m is remarkably intransi-
gent to assembly into amyloid ﬁbrils at neutral pH,
remaining predominantly monomeric for several
months at pH 7.5, 37  C, when incubated at protein
concentrations more than 20-fold higher than those
Fig. 1. Monomeric b2m plays a key role in
DRA. (A) Cartoon representation of human
MHC I (PDB code 3MYJ [136]) showing the
heavy chain (a1, a2, a3 in red) and the light
chain (b2m in blue). Highlighted are the resi-
dues Pro5, Pro14, Pro32, Pro72 and Pro90
(in green sticks, spheres) and the disulﬁde
bond between residues Cys25 and Cys80
(in yellow sticks). (B) Cartoon representation
of the solution structure of monomeric
native wild-type b2m (PDB code 2XKS [9])
showing b-strands A (6–11), B (21–28), C
(36–41), C¢ (44–45), D (50–51), E (64–70), F
(79–83) and G (91–94). Highlighted are the
residues Pro5, Pro14, Pro32, Pro72 and
Pro90 (in sticks, spheres) and the disulﬁde
bond between residues Cys25 and Cys80
(in sticks). N, N-terminus; C, C-terminus. (C)
Structures displaying a b-bulge and an
attached AB-loop: wild-type b2m (PDB code
1JNJ [7]) in red, H31Y (PDB code 1PY4 [15])
in green, W60G (PDB code 2VB5 [16]) in
blue, H13F (PDB code 3CIQ [55]) in yellow
and MHC I (PDB code 3MYJ [136]) in
magenta. (D) Structures displaying a straight
b-strand D: wild-type b2m (PDB code 1LDS
[11]) in red, L39W⁄W60F⁄W95F (PDB code
2D4D [137]) in green, wild-type b2m (PDB
code 2D4F [137]) in blue, wild-type b2m
(PDB code 2YXF [12]) in yellow, W60G
(PDB code 2Z9T [16]) in magenta,
W60C (PDB code 3DHJ [14]) in cyan, D59P
(PDB code 3DHM [14]) in orange, W60G
(PDB code 3EKC [14]) in wheat,
K58P⁄W60G (PDB code 3IB4 [121]) in black
and P32A (PDB code 2F8O [58]) in grey.
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consequence of these ﬁndings, factors have been
sought that could facilitate protein aggregation of b2m
in vivo, including the age of patients [27], the duration
of kidney failure [28], the dialysis procedure itself [29–
31], post-translational modiﬁcations of full-length b2m
[32–40] and bimolecular collision between b2m and
biological molecules abundant in osteoarticular tissues
or encountered during dialysis [26,41–51]. As a result,
a multitude of factors have been shown to enhance the
aggregation of b2m in vitro and are implicated in vivo,
including Cu
2+ [47,52–59], glycosaminoglycans
[26,41,60], lysophosphatidic acid [49], non-esteriﬁed
fatty acids [48,50] and collagen [41,42,61].
Amyloid formation of b2m under physiological pH
conditions (around pH 7.0) commences from the fully
folded native protein state [62]. Analysis of the ther-
modynamic stability of native wild-type b2m and an
array of variants, however, showed no correlation
between the thermodynamic stability of b2m and its
potential to assemble into amyloid-like ﬁbrils in vitro
[62]. Instead, the formation of one or more non-native
precursors that are accessible by dynamic ﬂuctuations
from the native protein is required before aggregation
can occur [9,18–20,63–69]. Such ﬂuctuations may
expose aggregation-prone sequences normally seques-
tered in the native structure [70], consistent with local
and⁄or more global unfolding events being a common
feature in the aggregation mechanisms of globular pro-
teins [58,67,71–80].
Peptidyl–prolyl isomerization initiates
b2m amyloid assembly at physiological
pH
In pioneering work, Chiti et al. [81] used a series of
spectroscopic probes to show that wild-type b2m folds
via two structurally distinct intermediates, known as I1
Fig. 2. Schematic of the key processes
which result in the pathological symptoms
experienced in DRA (reproduced, with
permission, from [138]).
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intermediate along the folding reaction coordinate, I1,
is populated within 5 ms of dilution of the protein
from denaturant. This species shows substantial ele-
ments of non-random structure and contains a disor-
ganized hydrophobic core in which several
hydrophobic residues remain exposed to solvent [81].
The second folding intermediate, I2, forms within milli-
seconds of the population of I1 and displays native-like
secondary structure and ordered packing of side chains
within the hydrophobic core. Further folding of I2
occurs on a timescale of seconds to minutes at 30  C,
suggesting substantial energetic barriers to the attain-
ment of the globular native fold [62,81]. Although
folding of wild-type b2m is a cooperative process as
judged by equilibrium denaturation [81], I2 nonetheless
accumulates, reaching a population of about 14 ± 8%
at equilibrium at pH 7.4, 30  C, as judged by capillary
electrophoresis [82]. Importantly, the concentration of
I2 was found to correlate with the rate of elongation
using seeds formed from ex vivo amyloid ﬁbrils at pH
7.4, 30  C, consistent with this native-like folding inter-
mediate being directly (or indirectly via further confor-
mational changes) capable of amyloid elongation [82].
A slow folding intermediate, reminiscent of I2, has also
been described by others [34,83].
Building on the observations made by Chiti and col-
leagues [82], more detailed studies of the folding and
unfolding mechanism of wild-type b2m, combined with
mutagenesis of the sequence, demonstrated that the
transition between the slow folding intermediate I2 and
the native fold is rate limited by trans to cis isomeriza-
tion of the His31-Pro32 peptide bond, which led to the
kinetically trapped intermediate being termed IT [67–
69]. Consistent with these ﬁndings, folding studies of a
variant of b2m in which Pro32 is replaced with Val
using manual mixing experiments at low temperature
(2.8–4.0  C) monitored by CD and NMR revealed that
the slow folding step is abolished, trapping b2mi na
non-native species presumably with a trans His31-
Val32 peptide bond [68]. Pro32 is highly conserved in
b2m in different organisms [84] and trans to cis pept-
idyl–prolyl isomerization at this site has been shown
previously to be responsible for the slow refolding
commonly found in other immunoglobulin domains
[85–91]. Interestingly, however, P32V b2m is not able
to elongate amyloid ﬁbrillar seeds in vitro or to nucleate
ﬁbril formation, suggesting that a trans His31-Xaa
peptide bond is necessary, but not sufﬁcient, to endow
b2m with its amyloidogenic properties [68].
To gain a more detailed understanding of the kinetic
folding mechanism of b2m and the role of different
partially folded species in linking the folding and
aggregation energy landscapes, Jahn and co-workers
[67] analysed the folding and unfolding kinetics of b2m
under an array of conditions, including analysis of the
folding mechanism of the variant P32G. Using global
analysis of the resulting kinetic data, the authors pro-
posed a ﬁve-state model for the folding mechanism of
wild-type b2m involving parallel folding pathways initi-
ated from cis or trans His31-Pro32 in the unfolded
state [67]. The ﬁve-state model has been challenged by
Sakata and co-workers [69] who proposed that a sim-
pler four-state model satisﬁes their obtained micro-
scopic and macroscopic rates of b2m unfolding and
refolding using chevron analysis. In particular, using
their approach Sakata et al. were unable to detect
spectroscopically the accumulation of the folding inter-
mediate containing a native cis-His31-Pro32 peptide
bond (IC), suggesting that this species is non-existent
or populated to levels below the detection limit.
Despite these differences, both folding models suggest
that IT is low but signiﬁcantly populated under physio-
logical conditions at equilibrium, consistent with the
poor ability of wild-type b2m to elongate ﬁbrillar seeds
at neutral pH in vitro [26,67]. Replacement of Pro32
with glycine (P32G) resulted in a simple three-state
folding mechanism in which an intermediate, presum-
ably with a trans His31-Gly32 peptide bond akin to IT,
accumulates during folding, reaching an equilibrium
concentration of approximately 30% [67]. Importantly,
by titrating the population of IT populated at equilib-
rium for the wild-type protein and P32G by varying
the solution conditions, Jahn et al. [67] showed that
the population of IT correlates with the rate of ﬁbril
elongation in vitro, suggesting that IT is a key link
between the folding and aggregation energy landscapes
for this protein. This could occur directly by this spe-
cies showing an ability to elongate amyloid seeds, or
indirectly via further conformational excursions to
other species accessible from this folding intermediate
[9,20,66,67]. Interrogation of the conformational prop-
erties of P32G using NMR suggested large conforma-
tional changes involving residues in the BC- and FG-
loops, the D-strand and the N-terminal region of the
protein that presumably arise from the isomerization
of Pro32 and subsequent partial unfolding of the pro-
tein [67]. These regions map precisely to the regions
reported previously to be perturbed in the kinetic fold-
ing intermediate IT, suggesting a close structural rela-
tionship of the two species [67].
The intransigence of wild-type b2m to form amyloid
ﬁbrils when incubated for extended periods of time at
neutral pH at concentrations substantially higher than
those found in vivo [21,25,26] can be rationalized in
light of the ﬁnding that the amyloidogenic precursor,
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concentrations at equilibrium in the wild-type protein
under ambient conditions [25,67,82]. In order to
explore the thermodynamics and kinetics of amyloid
assembly from b2m at physiological pH in vitro,
therefore, a plethora of conditions have been used to
increase the population of species akin (but not neces-
sarily identical) to IT at equilibrium. These include the
addition of Cu
2+ ions and urea [46,47,53,92], organic
solvents [60,83], collagen [41,42], glycosaminoglycans
or other biologically relevant factors [26,60,93], SDS
or lysophospholipids [48–51,94]. Changes in the physi-
cochemical environment, including ultrasonication [95],
heat treatment [96], high salt and stirring⁄agitation
[97], have also been employed. These apparently very
different conditions have in common the principle that
they perturb the equilibrium position of the cis⁄trans
His31-Pro32 peptide bond and hence enhance the
amyloidogenic potential of the wild-type protein
[25]. Mutations in the N- and⁄or C-terminal regions
of the sequence have also been shown to enhance
amyloid formation of b2m at physiological pH
[8,9,25,26,32,98,99], whilst other mutations that focus
on the DE-loop region demonstrated variable effects
on the thermodynamic stability of the protein depend-
ing on the amount of strain introduced
[14,16,20,100,101]. DE-loop mutations such as D59P
that introduce loop strain show a decreased folding
free energy compared with the wild-type protein and
an enhanced potential to aggregate, whereas a release
of loop strain such as in W60G leads to super-stable
variants which have reduced amyloidogenic features
[13,14,16]. However, DE-loop cleavage variants such
as DK58 or cK58 (which contain a speciﬁc cleavage at
Lys58 with or without removal of Lys58, respectively)
have been demonstrated to be highly aggregation-
prone [34,102–104]. Together these studies are
indicative of a fragile and delicate amino acid network
required for the stabilization of the cis isomer at
His31-Pro32 that is required both for binding to the
MHC I heavy chain [16] and to maintain a soluble
native structure for the monomeric protein.
b2m assembly mechanisms at atomic
resolution
Clinical studies have shown that dialysis patients trea-
ted with Cu
2+-free ﬁlter membranes have a > 50%
reduced incidence of DRA compared with patients
who were exposed to traditional Cu
2+-containing dial-
ysis membranes [27,105]. These studies suggest that
Cu
2+ ions may play a role in initiating or enhancing
aggregation of wild-type b2m in DRA. Indeed, Cu
2+
has been shown to bind to native human b2m with
moderate afﬁnity (Kapp = 2.7 lm) and speciﬁcity
(Cu
2+ >Z n
2+ >> Ni
2+) [46,106]. Binding involves
coordination to the imidizole ring of His31 [7,107].
Non-native states of wild-type b2m also bind Cu
2+
ions; in this case the three other histidines in the
sequence (His13, His51, His84) coordinate Cu
2+ with
a Kapp  41 lm [107]. As a consequence, binding of
Cu
2+ ions increases the concentration of non-native
(so-called ‘activated’) forms of monomeric b2m, named
by Miranker and co-authors as M*, which triggers the
formation of dimeric, tetrameric and hexameric species
(< 1 h) believed to be on-pathway to amyloid-like
ﬁbrils [47,106]. Cu
2+ binding is required for the
conformational changes leading to the formation of
M* and to the generation of early oligomeric species.
However, once these oligomeric species and subse-
quent ﬁbrillar aggregates are formed, Cu
2+ is not
essential for their stability [52,54,56,57,108]. By creat-
ing two variants, P32A and H13F, Miranker and col-
leagues [55,58] were able to crystallize dimeric and
hexameric forms of b2m (the latter after Cu
2+-induced
oligomerization). These studies revealed that dimeric
P32A and hexameric H13F contain a trans His31-
Ala32 and a trans His31-Pro32 peptide bond, respec-
tively. Each oligomer is composed of monomers that
retain a native-like fold, yet display signiﬁcant altera-
tions in the organization of aromatic side chains within
the hydrophobic core, most notably Phe30, Phe62 and
Trp60 (Fig. 3A,B, in blue), which the authors speculate
could be important determinants of amyloid assembly
[53,55,58]. How these static structures relate to the
transient intermediates formed during folding or popu-
lated during aggregation, however, remain unclear.
Importantly in this regard, P32A and H13F lack an
enhanced ability to assemble into amyloid ﬁbrils
compared with wild-type b2m [55,58], reminiscent of
the behaviour of P32V [68,69]. Despite containing a
trans His31-Xaa32 peptide bond, these species lack
structural and/or dynamical properties critical for
amyloid formation.
Increased conformational dynamics has emerged as
a common feature of the assembly of b2m monomers
into amyloid ﬁbrils at neutral pH from a wealth of
studies under varied solution conditions [9,10,18–
20,32,65–67,92,103,109], akin to the ﬁndings on
other proteins that also assemble into amyloid
ﬁbrils commencing from folded monomeric states
[64,71,73,76,77,80,110–116]. Accordingly, DN6 (in
which b2m is cleaved at Lys6) [32], cK58 and DK58
[34,102,103,117,118] and wild-type b2m in the presence
of SDS⁄2,2,2-triﬂuoroethanol (TFE)⁄other additives
[20,41,42,50,51,66,119] all exhibit decreased solubility,
b2-microglobulin ﬁbrillogenesis at physiological pH T. Eichner and S. E. Radford
3872 FEBS Journal 278 (2011) 3868–3883 ª 2011 The Authors Journal compilation ª 2011 FEBSFig. 3. Molecular description of the IT state using X-ray crystallography and high resolution solution NMR. (A) The ribbon overlay shows one
monomer of the hexameric crystal structure of H13F (PDB code 3CIQ [55], in blue) and the lowest energy structure of DN6 (PDB code 2XKU)
[9] (in red). The residues Phe30, Pro32, Trp60, Phe62 and His84 are highlighted in sticks. The dashed green box indicates a zoom-in for this
region shown in (B). (C)
1H–
15N HSQC of wild-type b2m in 18% (v⁄v) TFE at pH 6.6 and 33  C (reproduced, with permission, from [20]). Green
circles are assigned resonances for IT, while blue circles indicate the TFE induced, structurally disordered D state that is thought to be precur-
sor for ﬁbril elongation under these conditions. (D)
1H–
15N HSQC overlay of wild-type b2m (black) and DN6 (red) recorded in 25 mM sodium
phosphate buffer pH 7.5, 25  C. (E)
1H–
15N SOFAST HMQC overlay of DN6 (red) and the kinetic intermediate IT (green) recorded approximately
2 min after refolding was initiated (25 mM sodium phosphate buffer pH 7.5, 0.8 M residual urea, 25  C). Reproduced with permission from [9].
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enhanced amyloidogenicity at pH values close to phys-
iological. Of particular interest is the variant DN6,
since this species is found as a signiﬁcant component
( 26%) in ex vivo amyloid deposits and exhibits an
increased afﬁnity for collagen compared with the wild-
type protein, suggesting a role for this protein in the
development of DRA [61,120]. Pioneering work by
Esposito and colleagues showed that DN6 experiences
a global decrease in conformational stability compared
with wild-type b2m and, using molecular dynamics
simulations, the authors proposed that the D-strand
facilitates intermolecular interactions to form oligo-
meric assemblies prior to the development of long
straight amyloid ﬁbrils at pH 6.5, 37  C [32]. Similarly,
the variants cK58 and DK58 were found to be highly
aggregation-prone, presumably due to enhanced con-
formational dynamics, especially for strand D, and a
concomitant increase in concentration of the amyloido-
genic folding intermediates at equilibrium [34,103]. In
contrast, the mutation W60G which also lies in the
DE-loop diminishes the potential of this variant to
extend ﬁbrillar seeds of the human wild-type protein at
pH 7.4 in the presence of 20% (v⁄v) TFE [16], consis-
tent with the dynamics within this region of the pro-
tein playing a crucial role in b2m assembly at neutral
pH [13,14,19,20,66,121]. These studies therefore rein-
force the importance of interrogating the conforma-
tional dynamics of b2m and its truncation variants in
more detail in order to understand the aggregation
properties of this species and, more generally, how
other non-native species that retain a globular fold
aggregate in vitro and in vivo [116].
Major breakthroughs in understanding the proper-
ties that endow non-native states of b2m with their
amyloidogenic properties have arisen from NMR stud-
ies of wild-type b2m and several variants of the protein
by exploiting the capabilities of modern NMR meth-
ods for rapid and sensitive data acquisition
[7,9,11,20,32,55,58,66–68,103,109]. Accordingly, recent
studies of the folding kinetics of wild-type b2m using
real-time NMR combined with amino acid selective
labelling of Phe, Val and Leu provided the ﬁrst
glimpses of the amyloid precursor of b2m under condi-
tions close to physiological [109]. However, extensive
peak broadening caused by conformational dynamics
on a microsecond to millisecond timescale ruled out
detailed assignment and structure elucidation of IT.
Following on from this work, studies of the folding
kinetics of wild-type b2m in different concentrations of
TFE using real-time NMR revealed that the native
protein is generated with double exponential kinetics
from IT for all resonances studied, indicative of an
energy landscape that is more complex than the single
barrier suspected hitherto [66,67,69]. By contrast with
the behaviour of the wild-type protein, W60G folds to
the native state from IT with mono-exponential kinet-
ics, indicative of a more simple folding energy land-
scape for this less amyloidogenic variant [66]. Based on
these results, the authors propose that a species that is
more disordered than IT (named a ‘native-unlike’ or D
state), formed maximally in 20% (v⁄v) TFE, is respon-
sible for elongating wild-type b2m seeds [20]. The
wild-type protein under those conditions has also been
simulated using molecular dynamics [122]. Exploiting
the sensitivity of b2m conformations to the concentra-
tion of TFE, the authors were able to ﬁnd conditions
wherein IT is maximally populated from W60G, reach-
ing 30–40% population in 18% (v⁄v) TFE (at pH 6.6,
33  C), and were able to assign 63 backbone amide
resonances (out of 93 amide bonds) unambiguously for
this species (BMRB code 16587) (Fig. 3C) [20]. Incom-
plete assignment of the IT state in W60G and consider-
able peak overlap by native state resonances, however,
hampered the assignment of the backbone conforma-
tion of the peptidyl–prolyl bond at Pro32 and a more
detailed structural and dynamic characterization of this
intermediate [20].
Most recently, the difﬁculties in determining the
conformational properties of IT have been overcome
by using the b2m truncation variant DN6 as a struc-
tural mimic of this species (Fig. 3A,B, in red) [9,25].
High resolution NMR studies directly comparing the
1H–
15N HSQC spectra of DN6 and IT revealed that
the major species populated by DN6 in solution at pH
7.5, 25  C, closely resembles the transient folding inter-
mediate IT (Fig. 3D,E). Using DN6 as a structural
model for IT, full resonance assignment and structural
elucidation were possible, revealing the structural and
dynamical properties of this non-native conformer of
b2m. The results showed that under the conditions
employed DN6 retains a native fold but undergoes a
major re-packing of several side chains within the
hydrophobic core to accommodate the non-native
trans-conformation of the His31-Pro32 peptide bond
(Fig. 3A,B, in red). Intriguingly, the side chains
involved map predominantly to the same residues that
undergo structural reorganization in the presence of
Cu
2+ ions, although the precise packing of residues
remains different in many cases (Fig. 3A,B) [9,55,58].
Despite adopting a thermodynamically stable [9,25]
native-like topology, DN6 is a highly dynamic entity,
possessing only limited protection from hydrogen
exchange together with pH- and concentration-depen-
dent sensitivity of its backbone dynamics on a micro-
second to millisecond timescale. These data suggest
b2-microglobulin ﬁbrillogenesis at physiological pH T. Eichner and S. E. Radford
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late with an increase in its amyloidogenic properties
presumably by enabling the formation of one or more
rarely populated conformers that have an enhanced
potential to assemble into amyloid ﬁbrils [9,32,123].
One of the key events in this amyloid switch is proton-
ation of His84, which experiences a large pKa shift
from  4t o 7 upon peptidyl–prolyl isomerization of
the His31-Pro32 peptide bond (Fig. 4A) [9]. The
involvement of His84 in the initiation of b2m amyloid
Fig. 4. Prion-like conversion during amyloid formation. (A) Summary showing the structures of wild-type b2m (PDB code 2XKS) and a model
of IT. Above, keys for these conformational states. Native wild-type b2m (leftmost), shown above as a circle with cis His31-Pro32 (green C),
trans His13-Pro14 (blue C), His84 (orange circle) and the N-terminal region (residues 1–6, blue arrow). Backbone atoms of residues which
establish strong hydrogen bonding between b-strands A and B in the native state are shown in sticks. Upon dissociation of the N-terminal
region, the His31-Pro32 peptide bond is free to relax into the trans-conformation, causing further conformational changes that lead to the for-
mation of the non-native IT conformer (shown as a circle above a model of its structure). Protonation of His84 under mildly acidic conditions
(shown in red ball and stick and as an orange square in the model above), which lies adjacent to Pro32, enhances the amyloid potential of IT
further. Oligomerization of these aggregation-prone species then leads to the formation of b2m amyloid ﬁbrils. Assuming that the ﬁbrils
formed at neutral pH are structurally similar to those formed at acidic pH, as suggested by FTIR [135] and solid state NMR [133,134], large
conformational changes are required in order to transform the anti-parallel b-sheet arrangement of DN6 into the parallel in-register arrange-
ment of b-strands characteristic of b2m amyloid ﬁbrils, as reported recently [132] (reproduced, with permission, from [9]). (B) Summary
showing the consequences of b2m cleavage of the N-terminal hexapeptide that generates DN6 as a persistent IT state (PDB code 2XKU).
Once formed DN6 is able to nucleate and elongate its own ﬁbrils and also to cross-seed elongation of its ﬁbrillar seeds with the wild-type
protein, leading to the development of long straight amyloid-like ﬁbrils (the image of the ﬁbrils was redrawn from the cryo-EM structure of
b2m amyloid ﬁbrils from [139]). Furthermore, DN6 can transform the innocuous native state of b2m via bimolecular collision. The formation
of catalytic amounts of DN6 thus has been proposed to be a cataclysmic event during the development of DRA.
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computational methods [61]. Oligomeric structures
which become available after peptidyl–prolyl isomeri-
zation and exploration of conformational space upon
His84 protonation have been proposed previously in
association with Cu
2+ binding [55,58], in the presence
of dithiothreitol [124] or by the binding of nanobodies
[125]. Interestingly, the last two conditions result in the
formation of oligomers that are domain swapped, as
proposed hitherto for b2m assembly under native
conditions using computational methods [126] or Cu
2+
treatment [106]. Whether domain swapping occurs in
DRA, however, remains to be elucidated. Another
open question is the structural and dynamic similarities
and differences between trans intermediates formed
under different conditions (such as alterations of pH
and temperature, Cu
2+ treatment, mutagenesis (DN6)
or addition of organic solvent (TFE)) and how these
map to the structure determined for DN6 at neutral
pH [9] or that of the more ephemeral amyloid precur-
sors that form from this protein or from the folding
intermediate IT. Nonetheless, these data are suggestive
of a mechanism of assembly under different solution
conditions that contains many features in common.
Prion-like conversion during b2m
amyloid assembly
Despite the ﬁnding that DN6 comprises  26% of b2m
in amyloid deposits in patients with DRA, this species
is not found in the serum of people with renal dysfunc-
tion [127]. As a consequence of these ﬁndings,
formation of DN6 has been proposed to occur as a
post-assembly event [123]. Most recently, however, it
has been demonstrated that DN6 is not only able to
nucleate ﬁbrillogenesis efﬁciently in vitro at physiologi-
cal pH as discussed above (Fig. 4B) [9,25,26] but, as a
persistent trans-Pro32 state, DN6 is also able to
convert wild-type b2m into an aggregation-competent
conformer by bimolecular collision between the two
monomers (Fig. 4B) [9]. Accordingly, only catalytic
amounts (1%) of DN6 are sufﬁcient to convert signiﬁ-
cant quantities of the wild-type protein into amyloid
ﬁbrils (Fig. 4B). Detailed interrogation of bimolecular
collision between native wild-type b2m and DN6 using
NMR revealed the molecular mechanism by which this
prion-like templating might occur [9]. First, DN6 binds
speciﬁcally, but transiently, to native wild-type b2m,
possibly involving residues of b-strands A, B and D
and the DE-loop. This interaction changes the native
conﬁguration of Pro14 within the AB-loop which is
highly dynamic as indicated by molecular dynamics
simulations [63,122] and X-ray crystallography
(Fig. 1C,D). Pro14 dynamics have been shown hitherto
to be responsible for an alternative b2m conformation
in which the hydrogen bonding between b-strands A
and B is severely impaired [15]. Inter-strand hydrogen
bonding between those two strands, together with the
correct attachment of the N-terminal hexapeptide, has
been demonstrated to be crucial in maintaining a low
concentration of IT at equilibrium [25]. Binding of
DN6 to wild-type b2m, therefore, leads to the disrup-
tion of important interactions between the N-terminal
hexapeptide and the BC-loop, leading to accelerated
relaxation kinetics towards the amyloidogenic trans
His31-Pro32 isomeric state. The truncation variant
DN6 is thus capable of driving the innocuous native
wild-type protein into aggregation-competent entities,
reminiscent of the action of prions. Such an observa-
tion rationalizes the lack of circulating DN6 in the
serum and, given the natural afﬁnity of this species for
collagen (which is enhanced relative to wild-type b2m
[61]), explains why assembly of ﬁbrils occurs most
readily in collagen-rich joints. Rather than being an
innocuous post-assembly event, therefore, proteolytic
cleavage of b2m to create one or more species
truncated at the N-terminus could be a key initiating
event in DRA, enabling the formation of a species that
is not only able to assemble de novo into amyloid
ﬁbrils but can enhance ﬁbrillogenesis of wild-type b2m.
The latter is accomplished by initiating the ability of
the wild-type protein to nucleate its own assembly, or
by cross-seeding ﬁbril elongation of DN6 seeds with
wild-type monomers (Fig. 4). Identifying the proteases
responsible for the production of DN6 or using the
high resolution structure of DN6 as a target for the
design of small molecules able to intervene in assembly
may provide new approaches for therapeutic interven-
tion in DRA.
Outlook: towards a complete molecular
description of b2m amyloidosis
In this review we have highlighted the importance of
conformational dynamics for the initiation and devel-
opment of b2m amyloid formation commencing from
the natively folded state. Detailed analysis of the
folding, stability and amyloidogenicity of a number of
different proteins has revealed that a polypeptide chain
can adopt a diversity of structures within a multidi-
mensional energy landscape, the thermodynamics and
kinetics of which are dependent on the protein
sequence and solution conditions employed [128]. One
key feature that appears to identify amyloidogenic
proteins from their non-amyloidogenic counterparts is
a lack of structural cooperativity that is revealed by
b2-microglobulin ﬁbrillogenesis at physiological pH T. Eichner and S. E. Radford
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to millisecond timescale, often portrayed by increased
rates of proteolysis, hydrogen exchange and R2 NMR
relaxation rates [115]. Such motions may expose
sequences with high amyloid potential that are usually
hidden within the native structure [70] or may endow
surface properties that enable new protein–protein
interactions to form. Studies of b2m have contributed
substantially to this view, resulting most recently in a
high resolution structure for the amyloid-initiating
folding intermediate IT and the beginnings of a molec-
ular understanding of why increased conformational
dynamics make this species highly aggregation-prone
[9]. Rather than an innocuous post-assembly event, the
work suggests proteolytic cleavage as a cataclysmic
event that releases a species that is not only able to
spawn further aggregation-prone species but is also
able to convert the wild-type protein into an amyloido-
genic state via conformational conversion akin to the
activity famously associated with prions [129–131].
Finally, many studies of b2m amyloid assembly under
a wide range of conditions, some close to physiological
and others utilizing metal ions or solvent additives to
drive ﬁbrillogenesis at neutral pH, have together
revealed common principles of b2m self-assembly
which are related by the formation of non-native spe-
cies initiated by a cis to trans His31-Pro32 switch
despite the wide range of conditions employed. Further
work is now needed to deﬁne the origins of molecular
recognition between monomers and oligomers that
form as assembly progresses into amyloid ﬁbrils at
neutral pH and to deﬁne the extent of further confor-
mational changes required to form the cross-b struc-
ture of amyloid [132–135]. This will entail greater
structural knowledge about the multitude of protein
states populated on the folding and aggregation energy
landscapes and how these species are formed and inter-
connected.
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